Validation of quantitative assessment of florbetaben PET scans as an adjunct to the visual assessment across 15 software methods
暂无分享,去创建一个
A. Nelson | R. Gunn | P. Bourgeat | J. Lilja | N. Roé-Vellvé | J. Gómez-González | V. Doré | N. Koglin | S. Bullich | Aleksandar Jovalekic | M. Diemling | A. Stephens | A. Whittington | Mariana Lagos Quintana
[1] W. M. van der Flier,et al. Quantification of [18F]florbetaben amyloid‐PET imaging in a mixed memory clinic population: The ABIDE project , 2022, Alzheimer's & dementia : the journal of the Alzheimer's Association.
[2] Barry A. Siegel,et al. Quantitative analysis of 6,150 real‐world amyloid Positron Emission Tomography (PET) scans from the Imaging Dementia–Evidence for Amyloid Scanning (IDEAS) study , 2022, Alzheimer's & Dementia.
[3] W. M. van der Flier,et al. Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline , 2022, Nature Medicine.
[4] M. Mintun,et al. Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes , 2022, JAMA neurology.
[5] F. Barkhof,et al. Quantification of amyloid PET for future clinical use: a state-of-the-art review , 2022, European Journal of Nuclear Medicine and Molecular Imaging.
[6] S. Seo,et al. Finding the optimal cutoff value for amyloid β positivity using the iterative outlier method and concordance rate , 2021 .
[7] J. Molinuevo,et al. A multisite analysis of the concordance between visual image interpretation and quantitative analysis of [18F]flutemetamol amyloid PET images , 2021, European Journal of Nuclear Medicine and Molecular Imaging.
[8] C. Rowe,et al. Early detection of amyloid load using 18F-florbetaben PET , 2021, Alzheimer's research & therapy.
[9] K. Miwa,et al. Quantitative Evaluation of 18F-Flutemetamol PET in Patients With Cognitive Impairment and Suspected Alzheimer's Disease: A Multicenter Study , 2021, Frontiers in Neurology.
[10] J. Molinuevo,et al. Converging evidence for a “gray‐zone” of amyloid burden and its relevance , 2020 .
[11] Vincent Doré,et al. Non-negative matrix factorisation improves Centiloid robustness in longitudinal studies , 2020, NeuroImage.
[12] D. Berry,et al. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody , 2020, Alzheimer's Research & Therapy.
[13] G. Cheon,et al. Visual interpretation of [18F]Florbetaben PET supported by deep learning–based estimation of amyloid burden , 2020, European Journal of Nuclear Medicine and Molecular Imaging.
[14] A. Ciarmiello,et al. Impact of Tracer Retention Levels on Visual Analysis of Cerebral [18f]- Florbetaben pet Images. , 2020, Current radiopharmaceuticals.
[15] R. Lhommel,et al. Defining a Centiloid scale threshold predicting long-term progression to dementia in patients attending the memory clinic: an [18F] flutemetamol amyloid PET study , 2020, European Journal of Nuclear Medicine and Molecular Imaging.
[16] Young Hee Jung,et al. Concordance in detecting amyloid positivity between 18F-florbetaben and 18F-flutemetamol amyloid PET using quantitative and qualitative assessments , 2020, Scientific Reports.
[17] Mark E. Schmidt,et al. Quantitative amyloid PET in Alzheimer's disease: the AMYPAD prognostic and natural history study , 2020, Alzheimer's & dementia : the journal of the Alzheimer's Association.
[18] Elizabeth C Mormino,et al. Neuroanatomical spread of amyloid β and tau in Alzheimer’s disease: implications for primary prevention , 2020, Brain communications.
[19] Jun Pyo Kim,et al. Staging and quantification of florbetaben PET images using machine learning: impact of predicted regional cortical tracer uptake and amyloid stage on clinical outcomes , 2019, European Journal of Nuclear Medicine and Molecular Imaging.
[20] G. Farrar,et al. The Spatial-Temporal Ordering of Amyloid Pathology and Opportunities for PET Imaging , 2019, Journal of Nuclear Medicine.
[21] M. Andjelkovic,et al. Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer’s disease: a PET substudy interim analysis , 2019, Alzheimer's Research & Therapy.
[22] D. Holtzman,et al. Alzheimer Disease: An Update on Pathobiology and Treatment Strategies , 2019, Cell.
[23] O. Hansson,et al. Staging β-Amyloid Pathology With Amyloid Positron Emission Tomography. , 2019, JAMA neurology.
[24] C. Rowe,et al. Comparison of 18F-florbetaben quantification results using the standard Centiloid, MR-based, and MR-less CapAIBL® approaches: Validation against histopathology , 2019, Alzheimer's & Dementia.
[25] K. Blennow,et al. Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers , 2019, Alzheimer's Research & Therapy.
[26] C. Jack,et al. Multisite study of the relationships between antemortem [11C]PIB-PET Centiloid values and postmortem measures of Alzheimer's disease neuropathology , 2018, Alzheimer's & Dementia.
[27] R. Gunn,et al. Amyloid Load: A More Sensitive Biomarker for Amyloid Imaging , 2018, The Journal of Nuclear Medicine.
[28] Olivier Salvado,et al. Implementing the centiloid transformation for 11C-PiB and β-amyloid 18F-PET tracers using CapAIBL , 2018, NeuroImage.
[29] J. Dukart,et al. Rate of β-amyloid accumulation varies with baseline amyloid burden: Implications for anti-amyloid drug trials , 2018, Alzheimer's & Dementia.
[30] Jens Sörensen,et al. Spatial Normalization of 18F-Flutemetamol PET Images Using an Adaptive Principal-Component Template , 2018, The Journal of Nuclear Medicine.
[31] Chengjie Xiong,et al. Utilizing the Centiloid scale in cross-sectional and longitudinal PiB PET studies , 2018, NeuroImage: Clinical.
[32] D. Sharp,et al. Spatiotemporal Distribution of β-Amyloid in Alzheimer Disease Is the Result of Heterogeneous Regional Carrying Capacities , 2017, The Journal of Nuclear Medicine.
[33] Vincent Doré,et al. 18F-Florbetaben PET beta-amyloid binding expressed in Centiloids , 2017, European Journal of Nuclear Medicine and Molecular Imaging.
[34] John Seibyl,et al. Optimized classification of 18F-Florbetaben PET scans as positive and negative using an SUVR quantitative approach and comparison to visual assessment , 2017, NeuroImage: Clinical.
[35] J. Seibyl,et al. Yes we can analyse amyloid images - Now What? , 2017, European Journal of Nuclear Medicine and Molecular Imaging.
[36] M. Mintun,et al. Quantitation of PET signal as an adjunct to visual interpretation of florbetapir imaging , 2017, European Journal of Nuclear Medicine and Molecular Imaging.
[37] John Seibyl,et al. Impact of Training Method on the Robustness of the Visual Assessment of 18F-Florbetaben PET Scans: Results from a Phase-3 Study , 2016, The Journal of Nuclear Medicine.
[38] Chloe Hutton,et al. Classification of amyloid status using machine learning with histograms of oriented 3D gradients , 2016, NeuroImage: Clinical.
[39] Takamichi Murakami,et al. Performance of 11C-Pittsburgh Compound B PET Binding Potential Images in the Detection of Amyloid Deposits on Equivocal Static Images , 2015, The Journal of Nuclear Medicine.
[40] John Seibyl,et al. Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: Phase 3 study , 2015, Alzheimer's & Dementia.
[41] Ranjan Duara,et al. Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density. , 2015, JAMA neurology.
[42] C. Rowe,et al. Comparison of MR-less PiB SUVR quantification methods , 2015, Neurobiology of Aging.
[43] Robert A. Koeppe,et al. The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET , 2015, Alzheimer's & Dementia.
[44] John Seibyl,et al. Aβ imaging with 18F-florbetaben in prodromal Alzheimer's disease: a prospective outcome study , 2014, Journal of Neurology, Neurosurgery & Psychiatry.
[45] Olivier Salvado,et al. MR-Less Surface-Based Amyloid Assessment Based on 11C PiB PET , 2014, PloS one.
[46] Elizabeth C Mormino,et al. Not quite PIB-positive, not quite PIB-negative: Slight PIB elevations in elderly normal control subjects are biologically relevant , 2012, NeuroImage.